Skip to main content

Table 6 Added predictive value of biomarkers over already known predictors for time-averaged disease activity (DAS28) over 5 years of treatment

From: The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Item B 95% CI Standardized beta P R 2
Intercept 1.90 0.99 to 2.81   0.000  
Treatment strategy -0.29 -0.62 to 0.03 -0.16 0.076 0.076
RF positive 0.35 0.02 to 0.68 0.18 0.040 0.098
Baseline disease activity 0.25 0.10 to 0.40 0.30 0.001 0.169
EULAR good response -0.84 -1.30 to -0.37 -0.46 0.001  
EULAR moderate response -0.19 -0.64 to 0.25 -0.11 0.393 0.322
CPII change 1 yr to baseline 0.18 -0.08 to 0.43 0.12 0.178 0.335
  1. EULAR nonresponse was used as reference category. 95% CI, 95% confidence interval; RF, rheumatoid factor.